| __timestamp | CRISPR Therapeutics AG | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 31073000 |
| Thursday, January 1, 2015 | 13403000 | 43216000 |
| Friday, January 1, 2016 | 31056000 | 50679000 |
| Sunday, January 1, 2017 | 35845000 | 79171000 |
| Monday, January 1, 2018 | 48294000 | 168218000 |
| Tuesday, January 1, 2019 | 63488000 | 210796000 |
| Wednesday, January 1, 2020 | 88208000 | 203613000 |
| Friday, January 1, 2021 | 102802000 | 234273000 |
| Saturday, January 1, 2022 | 102464000 | 265784000 |
| Sunday, January 1, 2023 | 76162000 | 344501000 |
| Monday, January 1, 2024 | 72977000 |
Unleashing the power of data
In the ever-evolving biotech industry, understanding financial trends is crucial. Over the past decade, Insmed Incorporated and CRISPR Therapeutics AG have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, peaking in 2023 with a 344% increase from 2014. In contrast, CRISPR Therapeutics experienced a more moderate growth of approximately 1,400% during the same period, with a notable dip in 2023.
This divergence highlights Insmed's aggressive expansion strategy, possibly reflecting increased investment in marketing and administrative capabilities. Meanwhile, CRISPR's expenses suggest a more cautious approach, potentially focusing on strategic cost management. These insights provide a window into the operational priorities of these biotech giants, offering valuable lessons for investors and industry analysts alike.
Comparing SG&A Expenses: Novartis AG vs Insmed Incorporated Trends and Insights
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.